Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Summary

The objective of this study is to explore the effects of darifenacin in patients with multiple sclerosis and neurogenic detrusor overactivity. The efficacy, safety and tolerability of darifenacin are already well established in idiopathic detrusor overactivity. Patients with multiple sclerosis and neurogenic detrusor overactivity without detrusor-sphincter-dyssynergia (DSD) will be allocated to darifenacin therapy.

Timeline

Start

2007-02

Primary completion

2007-10

Completion

2007-10

Outcome

Outcome not reported

Stopped (Enrollment): “The enrollment rate at most centers was unlikely to result in the recruitment of the planned sample size of 40 evaluable subjects.”

Drugs

Indications